Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $416000.0.

  • CG Oncology's Depreciation & Amortization (CF) rose 188095.24% to $416000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $596000.0, marking a year-over-year increase of 155555.56%. This contributed to the annual value of $32000.0 for FY2024, which is 8823.53% up from last year.
  • Per CG Oncology's latest filing, its Depreciation & Amortization (CF) stood at $416000.0 for Q3 2025, which was up 188095.24% from $156000.0 recorded in Q2 2025.
  • CG Oncology's 5-year Depreciation & Amortization (CF) high stood at $416000.0 for Q3 2025, and its period low was $4000.0 during Q1 2023.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $6000.0 (2023), whereas its average is $64500.0.
  • Per our database at Business Quant, CG Oncology's Depreciation & Amortization (CF) changed by 0.0% in 2024 and then surged by 212857.14% in 2025.
  • Quarter analysis of 3 years shows CG Oncology's Depreciation & Amortization (CF) stood at $4000.0 in 2023, then soared by 425.0% to $21000.0 in 2024, then surged by 1880.95% to $416000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $416000.0 for Q3 2025, versus $156000.0 for Q2 2025 and $24000.0 for Q1 2025.